Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Average Rating of “Hold” from Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned an average recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $9.3333.

Several analysts recently issued reports on the company. Zacks Research lowered Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Ascendiant Capital Markets lifted their price target on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Finally, Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th.

Aytu BioPharma Stock Performance

AYTU stock opened at $2.30 on Monday. The firm has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $2.32. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $3.07. The stock has a market cap of $24.68 million, a P/E ratio of -0.60 and a beta of 0.37. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). The company had revenue of $15.17 million during the quarter, compared to analysts’ expectations of $12.17 million. Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AYTU. AWM Investment Company Inc. acquired a new stake in shares of Aytu BioPharma in the 2nd quarter valued at $1,351,000. Stonepine Capital Management LLC raised its holdings in Aytu BioPharma by 75.3% during the second quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after buying an additional 348,955 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Aytu BioPharma during the third quarter valued at about $117,000. FNY Investment Advisers LLC acquired a new stake in shares of Aytu BioPharma in the second quarter worth about $78,000. Finally, Two Sigma Investments LP boosted its stake in shares of Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after acquiring an additional 33,701 shares in the last quarter. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.